Just weeks after winning approval from the U.S. Food and Drug Administration for its Alzheimer's drug Aduhelm — a decision that continues to be mired in controversy — Biogen Inc. (Nasdaq: BIIB) has scored breakthrough therapy designation for another, similar drug called lecanemab.